Free Trial

Neurogene (NGNE) Stock Price, News & Analysis

Neurogene logo
$22.72 -0.09 (-0.39%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$22.82 +0.10 (+0.44%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neurogene Stock (NASDAQ:NGNE)

Key Stats

Today's Range
$22.01
$23.17
50-Day Range
$14.95
$23.09
52-Week Range
$6.88
$74.49
Volume
75,610 shs
Average Volume
194,481 shs
Market Capitalization
$323.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.17
Consensus Rating
Moderate Buy

Company Overview

Neurogene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

NGNE MarketRank™: 

Neurogene scored higher than 67% of companies evaluated by MarketBeat, and ranked 308th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neurogene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Neurogene's stock forecast and price target.
  • Earnings Growth

    Earnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurogene is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurogene is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neurogene has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Neurogene's valuation and earnings.
  • Percentage of Shares Shorted

    18.81% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Neurogene has recently decreased by 1.78%, indicating that investor sentiment is improving.
  • Dividend Yield

    Neurogene does not currently pay a dividend.

  • Dividend Growth

    Neurogene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.81% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Neurogene has recently decreased by 1.78%, indicating that investor sentiment is improving.
  • News Sentiment

    Neurogene has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Neurogene this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    3 people have added Neurogene to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,975.00 in company stock.

  • Percentage Held by Insiders

    Only 9.92% of the stock of Neurogene is held by insiders.

  • Percentage Held by Institutions

    52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurogene's insider trading history.
Receive NGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.

NGNE Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

NGNE Stock Analysis - Frequently Asked Questions

Neurogene's stock was trading at $22.86 on January 1st, 2025. Since then, NGNE shares have decreased by 0.6% and is now trading at $22.72.

Neurogene Inc. (NASDAQ:NGNE) issued its earnings results on Friday, May, 9th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.03.

Top institutional shareholders of Neurogene include Blair William & Co. IL (0.93%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn, Christine Mikail Cvijic and Stuart Cobb.
View institutional ownership trends
.

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON).

Company Calendar

Last Earnings
5/09/2025
Today
7/27/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NGNE
Previous Symbol
NASDAQ:NGNE
CIK
1404644
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$72.00
Low Price Target
$24.00
Potential Upside/Downside
+103.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.14 million
Net Margins
N/A
Pretax Margin
-8,742.70%
Return on Equity
-36.16%
Return on Assets
-32.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.03
Quick Ratio
21.03

Sales & Book Value

Annual Sales
$925 thousand
Price / Sales
350.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$20.89 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
14,262,000
Free Float
12,602,000
Market Cap
$324.03 million
Optionable
Optionable
Beta
1.51
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:NGNE) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners